| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
Myristic acid-d27 targets the same lipid metabolic pathways as the natural compound. It is a substrate for acyl-CoA synthetase, which activates it to myristoyl-CoA. It subsequently targets N-myristoyltransferase (NMT), an essential enzyme that catalyzes the attachment of myristate to the N-terminal glycine residues of proteins (myristoylation). As a tracer, it is an analytical target used to quantify these processes via mass spectrometry.
|
|---|---|
| ln Vitro |
In vitro, Myristic acid-d27 is used as a metabolic tracer in cell culture. It is added to media (typically conjugated to BSA, 1:1 molar ratio) of macrophages, adipocytes, or cancer cells at concentrations ranging from 10-100 uM. It incorporates into cellular lipids (triglycerides, phospholipids, cholesterol esters). Researchers measure the incorporation rate of the d27 label into these fractions by LC-MS to study lipid droplet formation, fatty acid oxidation, or membrane remodeling.
|
| ln Vivo |
In vivo, Myristic acid-d27 is administered to animal models to study lipid metabolism and trafficking. When orally administered (e.g., 50-100 mg/kg in olive oil) or injected intravenously, it follows the same absorption and distribution pathways as dietary saturated fats. It is used to trace the contribution of exogenous myristate to adipose tissue storage, hepatic fat accumulation, and milk fat synthesis in lactating animals. It also serves as a tracer for protein myristoylation in tissues.
|
| Enzyme Assay |
The standard workflow involves lipid extraction from biological samples (plasma, liver, adipose tissue). The sample is homogenized in chloroform:methanol (2:1, v/v) containing Myristic acid-d27 as an internal standard. After washing with water and centrifugation, the organic phase is collected and dried under nitrogen. For total fatty acid analysis, the extract is transmethylated using methanolic HCl or boron trifluoride-methanol to produce fatty acid methyl esters (FAMEs). FAMEs are extracted into hexane and analyzed by GC-MS.
|
| Cell Assay |
Cells (e.g., 3T3-L1 adipocytes or HepG2 hepatocytes) are cultured in low-serum or serum-free medium to reduce background lipids. Cells are treated with Myristic acid-d27 complexed with fatty acid-free BSA (5:1 molar ratio of BSA:fatty acid) for 1-24 hours. Cells are washed with cold PBS containing 0.5% BSA (to remove unbound fatty acids) followed by PBS alone. Lipids are extracted using hexane:isopropanol (3:2, v/v). The extract is analyzed by shotgun lipidomics or LC-MS.
|
| Animal Protocol |
C57BL/6 mice are fasted overnight to clear circulating chylomicrons. Myristic acid-d27 is administered via oral gavage (dissolved in corn oil, 50 mg/kg body weight). Blood is collected at 0, 1, 2, 4, 6 hours post-gavage. At endpoint, tissues (liver, white adipose tissue, brown adipose tissue) are collected and flash-frozen. Tissues are homogenized, lipids are extracted, and the isotopic enrichment of myristate in different lipid classes (triacylglycerol, phospholipids) is determined by GC-MS.
|
| ADME/Pharmacokinetics |
Myristic acid-d27 behaves identically to unlabeled myristic acid. Oral absorption in rodents is approximately 70-90%. It is incorporated into chylomicrons for lymphatic transport. Plasma clearance is moderate, with a half-life of several hours depending on tissue uptake. As a saturated fatty acid, it is not used for beta-oxidation as readily as unsaturated fats but is a primary substrate for protein myristoylation. It is stored in adipose tissue. Myristic acid-d27 is non-toxic at tracer doses.
|
| Toxicity/Toxicokinetics |
The unlabeled parent compound, Myristic Acid, has an acute oral LD50 > 5000 mg/kg in rats, indicating very low toxicity. It is not classified as a carcinogen or mutagen. It may cause skin or eye irritation upon direct contact, but the deuterated form is handled similarly.
|
| References | |
| Additional Infomation |
Tetradecanoic acid-d27 is a C14 straight-chain saturated fatty acid in which aliphatic hydrogen atoms are replaced by deuterium atoms. It is a metabolite of both bacteria and fungi. It is a deuterated fatty acid, a long-chain fatty acid, and a straight-chain saturated fatty acid, functionally related to tetradecanoic acid.
Myristic acid-d27 is not a drug; it is a research reagent. It has no clinical trial status or FDA approval for therapy. It is extensively used in lipidomics, metabolomics, and proteomics research. Due to the incorporation of deuterium, it provides a distinct mass shift of +27 Da, allowing clear separation from endogenous myristic acid. It is a high-value tool for studying the biochemistry of protein lipidation, specifically N-myristoylation, which is a target for antifungal and anticancer drug development. CAS# 60658-41-5, Molecular Formula: C14D27HO2. |
| Molecular Formula |
C14HD27O2
|
|---|---|
| Molecular Weight |
255.54
|
| Exact Mass |
255.378
|
| CAS # |
60658-41-5
|
| Related CAS # |
Myristic acid; 544-63-8; Myristic acid-d2; 30719-21-2
|
| PubChem CID |
16212357
|
| Appearance |
White to off-white solid
|
| Density |
1.005g/cm3
|
| Boiling Point |
250ºC100 mm Hg(lit.)
|
| Melting Point |
52-54ºC(lit.)
|
| Flash Point |
>230 °F(lit.)
|
| Index of Refraction |
1.451
|
| LogP |
4.772
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
12
|
| Heavy Atom Count |
16
|
| Complexity |
155
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCCCCCCCCCCCCC(=O)O
|
| InChi Key |
TUNFSRHWOTWDNC-RZVOLPTOSA-N
|
| InChi Code |
InChI=1S/C14H28O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14(15)16/h2-13H2,1H3,(H,15,16)/i1D3,2D2,3D2,4D2,5D2,6D2,7D2,8D2,9D2,10D2,11D2,12D2,13D2
|
| Chemical Name |
2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,11,11,12,12,13,13,14,14,14-heptacosadeuteriotetradecanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.9133 mL | 19.5664 mL | 39.1328 mL | |
| 5 mM | 0.7827 mL | 3.9133 mL | 7.8266 mL | |
| 10 mM | 0.3913 mL | 1.9566 mL | 3.9133 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
